Case Report

Cardiac arrest caused by rapidly increasing ascites in a patient with TAFRO syndrome: a case report

Masatoshi Okumura, Atsushi Ujiro, Yasunori Otsuka, Hiroshi Yamamoto, Sho Wada, Hirofumi Iwata, Toshiaki Kan, Seiji Miyauchi, Atsushi Hashimoto, Yuko Sato, Yoshihito Fujita, Yoshihiro Fujiwara, and Hideki Shimaoka

1Department of Anesthesiology, Aichi Medical University, Aichi, and 2Department of Intensive Care Medicine, Osaka-City General Hospital, Osaka, Japan

Case: Thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly (TAFRO) syndrome is a newly defined systemic inflammatory disorder with gradual progression of symptoms. A 59-year-old man with fever and ascites of unknown cause developed sudden-onset shock and respiratory failure in the general ward. Cardiac arrest immediately followed. Although he was resuscitated, frequent administration of adrenaline was required to maintain his blood pressure. His circulation was most effectively stabilized by drainage of fluid from his distended abdomen. The volume of discharged ascites reached 4,000 mL at that time, and several liters continued to be discharged for >1 month. The diagnosis of TAFRO syndrome was based on the clinical features and laboratory and histological findings.

Outcome: The ascites volume and concentrations of inflammatory parameters decreased with treatment using several immunosuppressive agents.

Conclusion: The newly defined TAFRO syndrome may be life-threatening. Patients should be monitored for progression to shock and cardiac arrest, especially those with rapidly increasing ascites.

Key words: Ascites, giant lymph node hyperplasia, heart arrest, intra-abdominal hypertension

INTRODUCTION

Thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly (TAFRO) syndrome is a newly defined systemic inflammatory disorder first reported in 2010. This syndrome is considered a variant of multicentric Castleman’s disease, but its pathogenetic mechanism remains unknown. Although approximately 30 cases of TAFRO syndrome have been reported, many involved patients on immunosuppressive therapies such as corticosteroids, anti-interleukin-6 (anti-IL-6) receptor antibody (tocilizumab), and cyclosporin A. The diagnostic criteria, severity classification, and treatment strategy were recently announced by a Japanese group (Table 1). The mortality rate is 11–12%, and death often occurs after a relatively long disease course. The main causes of death are multiple organ dysfunction unresponsive to immunosuppressive agents and severe infection caused by an immunocompromised state. No reports have described shock and cardiac arrest due to rapidly increasing ascites. We herein report a case involving a patient with TAFRO syndrome that progressed to cardiac arrest due to a large amount of ascites.

CASE

A 59-YEAR-OLD JAPANESE man was directly transferred to our hospital with fever, inflammation, ascites, and pleural effusion of unknown cause. He had no medical history other than infection by hepatitis B virus at 24 years of age. He had been well until 3 weeks before admission. One week before admission, he visited a local hospital because of fever (37.8°C) and watery diarrhea. His symptoms did not improve with broad-spectrum antibiotics. Although laboratory tests, blood cultures, whole-body computed tomography, echocardiography, and colonoscopy were carried out, the cause of the inflammation remained unknown.
On admission to our hospital, the patient presented with fever (>38.0°C), abdominal distension, and pitting edema of the legs. All laboratory findings are summarized in Table 2. Laboratory tests showed an increased white blood cell count, mild anemia, thrombocytopenia, hypoalbuminemia, an elevated C-reactive protein concentration, renal dysfunction, abnormal coagulation, increased serum IL-6, and increased plasma vascular endothelial cell growth factor. Tests for human herpesvirus 8, HIV, Rickettsia, Aspergillus, and Mycobacterium tuberculosis were negative. Immune serology tests and monoclonal immunoglobulin were normal. Tumor markers were negative. Blood and ascites cultures were negative. Computed tomography revealed ascites, bilateral pleural effusion, pericardial effusion, and mild hypertrophy of the bilateral kidneys, but no other enlarged organs or enlarged lymph nodes. Bone marrow biopsy showed increased megakaryocytes and mild reticulin fibrosis.

Table 1. Diagnostic criteria of thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly (TAFRO) syndrome

| Major categories                                      | Minor categories                                                                 |
|-------------------------------------------------------|-----------------------------------------------------------------------------------|
| (1) Anasarca                                           | (1) Lymph node: Castlemoan’s disease-like features                               |
| (2) Thrombocytopenia (platelet count ≤ 100,000/μL)    | (2) Bone marrow: reticulin myelofibrosis and/or increased number of megakaryocytes |
| (3) Systemic inflammation (fever and/or CRP ≥ 2 mg/dL) | (3) Mild organomegaly (hepatomegaly, splenomegaly, and lymphadenopathy)         |
|                                                       | (4) Progressive renal insufficiency                                               |

CRP, C-reactive protein.

Table 2. Laboratory data of a 59-year-old man with thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly (TAFRO) syndrome on admission to our hospital

| Complete blood count | Biochemistry | Virologic test | Immunologic test |
|----------------------|--------------|----------------|-----------------|
| WBC 19.6            | TP 5.0       | HIV            | IgG 1184 mg/dL  |
| Stab 9 %            | Albumin 1.5  | HBs-Ag         | IgA 224 mg/dL   |
| Seg 82 %            | BUN 40.5     | HBs-Ab         | IgM 19 mg/dL    |
| Eosi 0 %            | Creatinine 1.25 | HBC-Ab       | PAIgG 78.8 mg/10^7 calls |
| Baso 0 %            | T-Bil 1.1    | HCV-Ab         | RF (-)          |
| Mono 4 %            | AST 22       | HHV-8-DNA      | Anti-SS-A Ab (-) |
| Lymp 5 %            | ALT 12       |                | Anti-dsDNA Ab (-) |
| RBC 4.11 g/μL       | LDH 279      |                | aCL-β2GPI (-)   |
| Hb 11.6 g/dL        | ALP 532      |                | PR-3 ANCA (-)   |
| Ht 33.5 %           | Na 136       |                | MPO-ANCA (-)    |
| MCV 81.5 fl         | K 4.2        |                | IgG4 71 mg/dL   |
| MCH 28.2 pg         | Cl 103       |                |                 |
| MCHC 34.6 %         | Ca 7.5       |                |                 |
| Platelet 5.7 10^11/μL | CK 25       |                |                 |
| Coagulation test    |              |                |                 |
| PT 52.2 %           | T-Chol 68    |                |                 |
| PT-INR 1.29         | CRP 19.2     |                |                 |
| APTT 31.6 s         | Procalcitonin 3.77 |                |                 |
| Fbg 368 mg/dL       | Ferritin 1149 |                |                 |
| FDP 79.4 μg/mL      | IL-6 14      |                |                 |
| AT 42 %             | VEGF 119     |                |                 |
|                     | sIL-2R 1567 IU/mL |            |                 |

aCL-β2GPI, anticardiolipin–β2-glycoprotein I; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ANA, antinuclear antibody; APTT, activated partial prothrombin time; AST, aspartate aminotransferase; AT, antithrombin; Baso, basophils; BUN, blood urea nitrogen; CK, creatine kinase; CRP, C-reactive protein; dsDNA, double-stranded DNA; Eosi, eosinophils; Fbg, fasting blood glucose; FDP, fibrin degradation products; Hb, hemoglobin; HBC-Ab, hepatitis B core antibody; HBs-Ag, hepatitis B surface antibody; HBs-Ab, hepatitis B surface antigen; HCV-Ab, hepatitis C virus antibody; HHV-8, human herpesvirus 8; HT, hematocrit; Ig, immunoglobulin; IL, interleukin; LDH, lactate dehydrogenase; Lymp, lymphocytes; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; Mono, monocytes; MPO-ANCA, myeloperoxidase–antineutrophil cytoplasmic antibodies; PAIgG, platelet-associated immunoglobulin G; PR-3-ANCA, proteinase-3–antineutrophil cytoplasmic antibodies; PT, prothrombin time; PT-INR, prothrombin time–international normalized ratio; RBC, red blood cells; RF, rheumatoid factor; Seg, segmented neutrophils; sIL-2R, soluble interleukin-2 receptor; Stab, stab neutrophils; T-Bil, total bilirubin; T-Chol, total cholesterol; TP, total protein; VEGF, vascular endothelial growth factor; WBC, white blood cells.

Reference range: IL-6, <8 pg/mL; VEGF, <38.3 pg/mL; sIL-2R, 145–519 IU/mL; IgG4, 4–108 mg/dL.

© 2017 The Authors. *Acute Medicine & Surgery* published by John Wiley & Sons Australia, Ltd on behalf of Japanese Association for Acute Medicine.
Right inguinal lymph node biopsy showed lymph follicles with angiosclerosis, atrophic germinal centers, vascular proliferation, and infiltration of plasma cells. Moreover, the lymph node showed no evidence of monoclonal plasma cells. These findings were compatible with mixed-type Castleman's disease and TAFRO syndrome.

After admission, the fever and anasarca deteriorated despite administration of meropenem (1 g every 8 h), vancomycin (trough level of 15–20 µg/mL), doxycycline (100 mg every 12 h), and diuretics. On day 10, high-dose methylprednisolone (1 g/day for 3 days) was given, and prednisolone (1 mg/kg per day) was started on day 13. On day 17, the patient developed severe, sudden-onset respiratory distress and circulatory failure in the general ward and went into pulseless electrical activity within 1 min. After resuscitation and transport to the intensive care unit, his vital signs were unstable; his blood pressure was 67/35 mmHg, heart rate was 113 b.p.m., and oxygen saturation was 95% with 10-L oxygen flow. In the intensive care unit, frequent administration of 0.1 mg adrenaline was necessary to maintain his blood pressure. The most effective intervention to alleviate shock was drainage of fluid from his firm, distended abdomen. We were able to maintain his blood pressure by draining 4,000 mL of ascites. Following drainage, cardiac ultrasonography revealed a change from hypokinetic to normokinetic contraction of the left ventricle. The ascites reached a total of 7,300 mL on the first day, and drainage of an average of 3,576 mL/day of ascites continued for 6 weeks. Frequent treatment with crystalloid solutions, albumin, fresh frozen plasma, and plasma concentrate was required to reduce the circulatory volume, albumin concentration, and coagulation factors.

Fig. 1. Histological findings of bone marrow (A, B) and lymph node (C–F) in a 59-year-old man with thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly (TAFRO) syndrome. A, C, D, Hematoxylin–eosin staining. B, Silver staining. Kappa (E) and lambda (F) immunostaining.
On day 18, TAFRO syndrome was diagnosed according to the patient’s clinical features, laboratory data, and lymph node and bone marrow pathology. Treatment with 8 mg/kg tocilizumab every other week was initiated (Fig. 2). The serum IL-6 concentration increased further to 567 pg/mL at this point. Some inflammatory parameters improved for 5 days after initiating tocilizumab therapy; however, the anasarca worsened. Therefore, starting on day 24, cyclosporin A (250 mg/day) was given along with prednisolone and tocilizumab. The patient’s clinical symptoms and laboratory data gradually improved over 3 months. He was discharged home on day 112.

**DISCUSSION**

This case suggests that TAFRO syndrome is associated with acute life-threatening symptoms and leads to cardiac arrest due to rapidly increasing ascites. The mortality rate is 11–12%. In some reports, the cause of death was multiple organ failure secondary to deteriorating TAFRO syndrome over a 2-month period and septic shock associated with febrile neutropenia during an 8-month observation period. Although no reports have described acute life-threatening symptoms in patients with TAFRO syndrome, we assume that TAFRO syndrome may cause death in the acute phase. Some patients with TAFRO syndrome might die before diagnosis because TAFRO syndrome is uncommon and difficult to diagnose. Therefore, special attention should be given to patients with acute deterioration of TAFRO syndrome.

The diagnostic criteria for TAFRO syndrome were announced by two groups. Both these criteria emphasize clinical findings, however, one requires the histological feature in lymph node, the other does not. In the present case, anasarca, thrombocytopenia, systemic inflammation, Castleman’s disease-like feature in lymph node, reticulin myelofibrosis in bone marrow, and renal insufficiency are consistent with the criteria. Lymph node findings partially met the new criteria. However, according to past cases, there is no contradiction in the pathological findings of TAFRO syndrome. As a result, this case is diagnosed as TAFRO syndrome.

This syndrome leads to cardiac arrest caused by rapidly increasing ascites. Although 96–100% of patients with TAFRO syndrome develop anasarca, the quantity of ascites and incidence of cardiac arrest due to ascites have not been reported. In the present case, 4,000 mL of ascites was drained at the time of cardiac arrest, and 3,000–5,000 mL/day of ascites was continuously drained for 6 weeks despite immunosuppressive therapy. The causes of cardiac arrest include reduced venous return secondary to abdominal compartment syndrome by rapidly increasing ascites as well as impaired cardiac compliance and contractility by elevation of the diaphragm. In addition, hypovolemia due to a large amount of anasarca is a cause of reduced venous return.

The most common causes of abdominal compartment syndrome are abdominal surgery, abdominal trauma, retroperitoneal bleeding after aortic surgery, and burns to the abdominal wall. Only two cases of cardiac arrest due to acute abdominal compartment syndrome have been reported. In both cases, intestinal perforation was the cause of abdominal compartment syndrome and cardiac arrest during colonoscopy, and pulses were detected when the distended abdomen was decompressed using a 14-gauge needle. Indeed, a pulse was also detected after intra-abdominal drainage in the present case.

To the best of our knowledge, no reports of cardiac arrest caused by rapidly increasing ascites in patients with TAFRO syndrome have been published. The ascites associated with TAFRO syndrome might increase very rapidly and reach a rate of several liters per day. We should assume that these
changes lead to cardiac arrest secondary to abdominal compartment syndrome and hypovolemia. Both volume resuscitation and decompression of the distended abdomen are required as soon as possible in such patients.

CONFLICT OF INTEREST

NONE DECLARED.

REFERENCES

1 Takai K, Nikkuni K, Shibuya H, Hashidate H. Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Rinsho Ketsueki 2010; 51: 320–5. (in Japanese).
2 Masaki Y, Kawabata H, Takai K et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int. J. Hematol. 2016; 103: 686–92.
3 Yasuda S, Tanaka K, Ichikawa A et al. Aggressive TAFRO syndrome with reversible cardiomyopathy successfully treated with combination chemotherapy. Int. J. Hematol. 2016; 104: 512–8.
4 Fujiwara S, Mochinaga H, Nakata H et al. Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids. Int. J. Hematol. 2016; 103: 718–23.
5 Iwaki N, Fajgenbaum DC, Nabel CS et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am. J. Hematol. 2016; 91: 220–6.
6 Souadka A, Mohsine R, Ifrine L, Belkouchi A, El Malki HO. Acute abdominal compartment syndrome complicating a colonoscopic perforation: a case report. J. Med. Case Rep. 2012; 6: 51.
7 Peppriell JE, Bacon DR. Acute abdominal compartment syndrome with pulseless electrical activity during colonoscopy with conscious sedation. J. Clin. Anesth. 2000; 12: 216–9.